Product Datasheet

BAY-593

Catalog No. **BP-02274** · CAS **2413020-56-9** · Form **free base** · Physical state **other** · Color **White to off-white** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
YAP; GGTase	**Cancer**

Molecular formula	$C_{26}H_{31}F_3N_2O_3$
Molecular weight	**476.5311**

STRUCTURE



DESCRIPTION

BAY-593 is an orally active inhibitor of geranylgeranyltransferase-I (GGTase-I) that effectively blocks the activation of Rho-GTPases, leading to the inactivation of YAP1/TAZ signaling pathways and demonstrating significant antitumor activity. In cellular assays, BAY-593 exhibits potent antiproliferative effects, with an IC50 of 38.4 nM in HT-1080 fibrosarcoma cells and 564 nM in MDA-MB-231 breast cancer cells.

BIOLOGICAL ACTIVITY

In Vitro

BAY-593 (0.5 nM-10 μM; 72 h) inhibits the proliferation of HT-1080 and MDA-MB-231 cells with the IC50 values of 0.038 and 0.564 μM, respectively

In Vivo

BAY-593 (2.5-20 mg/kg; oral administration; 14 days) shows dose-dependent antitumor activity in HT-1080 fibrosarcoma and MDA-MB-231 triple negative breast cancer xenotransplantation mouse models

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 116.67 mg/mL

REFERENCES

[1]. Graham K, et al. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell Chem Biol. 2024 Mar 19:S2451-9456(24)00087-4.